Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Alexandre Bart

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
Plos One|November 13, 2020
Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: An observational retrospective studyJean Regina, Matthaios Papadimitriou-Olivgeris, Raphaël Burger, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammationFlorence Fellmann, Federica Angelini, Jacqueline Wassenberg, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
Plos One|November 13, 2020
Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: An observational retrospective studyJean Regina, Matthaios Papadimitriou-Olivgeris, Raphaël Burger, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammationFlorence Fellmann, Federica Angelini, Jacqueline Wassenberg, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Pageof 10